Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660829 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 536
- Enrollment target
NCT00660829: Completed Phase 3 study, sponsored by Meda Pharmaceuticals.
NCT00660829 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 536 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00660829, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 536 participants
- Enrollment target
Study Summary
The Purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than Placebo alone.
Primary Outcome
reflective total nasal symptom score consisting of runny nose, itchy nose, nasal congestion, and sneezing was assessed twice daily. Each symptom is rated on a scale from 0-3: 0=none, 1=mild, 2=moderate, and 3=severe. Total possible score is 24 per day. Least Means Square was controlled for study day as the within-patient effect, treatment group and site as the between-patient effects, treatment by-study day interaction, and baseline as co-variate
Interventions
- DRUG Placebo
- DRUG 0.15% Azelastine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 536 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
What the finished NCT00660829 record still lists
NCT00660829 is an interventional study that assigns participants to a tested intervention. The registered 536 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00660829 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00660829 about?
NCT00660829 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies". The Purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than Placebo alone.
What is the current status of trial NCT00660829?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 536 participants. The study started on 2007-12. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00660829?
The interventions under investigation include: Placebo (DRUG), 0.15% Azelastine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00660829?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00660829's enrollment target sits among peer trials
536 702nd of 2000 higher than 1,299 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
- NCT03772028 · 538 participants · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia